Antiviral Therapy · 2007 · 41 citations · 39 references
MedicineMolecular GeneticsPharmacologyAutoimmunityImmunogeneticsRheumatologyAntiretroviral TherapyAntiviral TherapyAutoimmune Disease Susceptibility GenesAutoimmune DiseasesInflammatory ArthritisRheumatoid ArthritisAllelic Association StudiesAssociation StudiesClinical Evidence ReviewClinical Pharmacology EvidenceGene-disease Association StudiesGenotype Association StudiesRheumatoid Arthritis PharmacotherapyTherapeutic Target Identification
The proliferation of published gene association studies of the CCR5delta32 mutation is of relevance to drug development of a CCR5 antagonist for HIV, in highlighting potential safety concerns. We conducted an initial review of all non-HIV gene association studies of CCR5-delta32, followed by detailed meta-analyses in the three disease areas most commonly reported. Our review indicated no consistent evidence of increased risk of susceptibility to hepatitis C virus infection or multiple sclerosis among individuals with CCR5-delta32 mutation, and suggested treatment with a CCR5 inhibitor is unlikely to have related adverse effects. There was, however, evidence to suggest rheumatoid arthritis as a potential therapeutic target for a CCR5 antagonist. Clinical evidence would be required to confirm these findings.
39
Bias in meta-analysis detected by a simple, graphical test
Matthias Egger, George Davey Smith, Martin Schneider et al. · BMJ · 1997 · 56.3K citations
Drug Discovery: A Historical Perspective
Jürgen Drews · Science · 2000 · 2.7K citations
The role of a mutant CCR5 allele in HIV–1 transmission and disease progression
Yaoxing Huang, William A. Paxton, Steven M. Wolinsky et al. · Nature Medicine · 1996 · 1.4K citations